Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LM-302 Combination Therapy in CLDN18.2-positive Advanced Gastrointestinal Cancer
NCT05934331Phase 2Recruiting
- Sponsor
- LaNova Medicines
- Start
- Jul 2023
- Primary completion
- Aug 2031
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tpx-4589 in gastrointestinal cancer, sponsored by LaNova Medicines. Started Jul 2023; status: recruiting.
02
Drugs
tpx-4589
03
Conditions
gastrointestinal cancer
Beyond the preview
Go deeper on NCT05934331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05934331.